Family-owned Dermapharm readies €350m Frankfurt IPO
Dermapharm Holding, the German pharmaceuticals company, has begun bookbuilding for its Frankfurt IPO with a price range that could value the business at up to €1.6bn.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts